Hikma Pharmaceuticals Plc Fixed income investor meetings (4443I)
March 25 2015 - 8:23AM
UK Regulatory
TIDMHIK
RNS Number : 4443I
Hikma Pharmaceuticals Plc
25 March 2015
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
TO ANY PERSON OR ADDRESS IN THE UNITED STATES, CANADA, JAPAN OR
AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE
UNLAWFUL.
Fixed income investor meetings
London, 25 March 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY),
(rated Ba1 Moody's / BB+ S&P, both stable), the
multinational pharmaceutical group, has mandated Citi (Global
Coordinator), Barclays, HSBC and National Bank of Abu Dhabi to
arrange a series of fixed income investor meetings in Europe and
the Middle East commencing on 27 March 2015. A Reg S Registered
USD-denominated benchmark transaction may follow subject to market
conditions. FCA/ICMA stabilisation applies.
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Director of Investor
Relations +44 (0)20 7399 2770/ +44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44
(0)20 7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44
7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
A RATING IS NOT A RECOMMENDATION TO BUY, SELL OR HOLD SECURITIES
AND MAY BE SUBJECT TO REVISION, SUSPENSION OR WITHDRAWAL AT ANY
TIME BY THE ASSIGNING RATING ORGANISATION. SIMILAR RATINGS FOR
DIFFERENT TYPES OF ISSUERS AND ON DIFFERENT TYPES OF SECURITIES DO
NOT NECESSARILY MEAN THE SAME THING. THE SIGNIFICANCE OF EACH
RATING SHOULD BE ANALYSED INDEPENDENTLY FROM ANY OTHER RATING.
NOTHING IN THIS ANNOUNCEMENT CONSTITUTES AN OFFER OF SECURITIES
FOR SALE, OR A SOLICITATION OF AN OFFER TO BUY SECURITIES, NOR
SHALL THERE BE ANY SALE OF SECURITIES IN THE UNITED STATES OR ANY
OTHER JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE
UNLAWFUL. THE SECURITIES TO WHICH THIS ANNOUNCEMENT RELATES HAVE
NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT
OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, SUBJECT TO CERTAIN
EXCEPTIONS, MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES.
This announcement is only addressed to and directed at persons
in member states of the European Economic Area who are qualified
investors (as defined in Directive 2003/71/EC, as amended (the
"Prospectus Directive")). This announcement has not been approved
by the UK Financial Conduct Authority. This announcement is not
being distributed to, and must not be passed on to, the general
public in the United Kingdom. Rather, this announcement is being
distributed on the basis that it is only being distributed to and
is only directed at: (i) persons who are Investment Professionals
as defined in Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion
Order"); (ii) persons falling within any of the categories of
persons described in Article 49 of the Financial Promotion Order;
and (iii) any other person to whom it may otherwise lawfully be
made in accordance with the Financial Promotion Order (all such
person together referred to as "relevant persons"). Any security,
investment or investment activity to which this announcement may
relate is only available to, and any invitation, offer, or
agreement to engage in such investment activity will be engaged in
only with: (i) in the United Kingdom, relevant persons; and (ii) in
any member state of the European Economic Area other than the
United Kingdom, qualified investors. No other person should rely on
it or any of its contents. This announcement is an advertisement
and is not a prospectus for the purposes of the Prospectus
Directive.
This announcement does not constitute or form a part of any
offer of, or solicitation to purchase, securities in the Kingdom of
Saudi Arabia. There will be no public offer of securities in the
Kingdom of Saudi Arabia.
--ENDS -
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRJAMTTMBTTBBA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024